VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co. Ltd. is a development-stage biomedical company focused on the research, development, and commercialization of products promoting wellness and a healthy lifestyle. Incorporated in Nevada on September 6, 2016, and formerly known as Shemn Corp., the company began operations in 2019. A change of ownership on January 21, 2020, led to a new management team and strategic direction, with the corporate name officially changing to VitaSpring Biomedical Co. Ltd. on April 21, 2020. The company's fiscal year ends on January 31. VitaSpring Biomedical aims to advance cellular and regenerative medicine by investing in research and development of stem cell-based applications and related biomedical innovations. Strategic objectives include establishing advanced medical research and cell production centers that meet Good Tissue Practice (GTP) standards and developing high-quality stem cell preparations for regenerative therapies and future drug development. The company collaborates with affiliated entities and research partners to support the mass production and commercialization of X.msc-related medical projects, including investigational new drugs and clinical trials involving X.exosome, a component used in skincare and regenerative formulations. Management anticipates that X.msc-based projects will achieve limited hospital implementation within approximately five years. Under new management, VitaSpring Biomedical has transitioned proprietary patent technologies into mass-production know-how for processing allogeneic mesenchymal stem cells (MSC) derived from the maternal placenta. Internally reported testing has indicated materially higher exosome concentration levels compared with certain conventional MSC cultures; however, these findings have not been independently validated or reviewed by regulatory authorities. The company intends to use this know-how to develop a stem cell bank designed to comply with applicable FDA regulations.